Prescription medicineZepbound is used together with a reduced-calorie diet and increased physical activity, and only on prescription.[1] This overview quotes the FDA label; it is not a substitute for it.
What is Zepbound used for?
Zepbound has two FDA-approved uses, both in adults and both alongside diet and exercise:[1]
- Weight management: “to reduce excess body weight and maintain weight reduction long term” in adults with obesity, or with overweight and at least one weight-related condition. The FDA's approval announcement defined these as a BMI of 30 or more, or 27 or more with a weight-related condition.[3]
- Obstructive sleep apnea: moderate to severe OSA in adults with obesity, approved December 20, 2024; the FDA called it the first medication for OSA.[4]
The Medication Guide says it is not known whether Zepbound is safe and effective in children, and that it should not be used with other tirzepatide products or any GLP-1 receptor agonist.[1]
How does Zepbound work?
Zepbound works by reducing appetite, so people eat fewer calories; it also slows stomach emptying, most noticeably after the first doses.[1] Its active ingredient, tirzepatide, switches on two hormone receptors, GIP and GLP-1, in the gut, pancreas and appetite centres of the brain. The label reports that the weight lost is more fat than lean mass.[1] The molecule itself is explained on tirzepatide peptide.
Zepbound at a glance
The essentials from the label and Lilly's published information are in one table.[1][7]
| Zepbound | |
|---|---|
| How it is taken | Injection under the skin once a week, any time of day |
| Doses | 2.5 mg for 4 weeks, then +2.5 mg steps (at least 4 weeks apart) to 5, 10 or 15 mg; 10 or 15 mg for sleep apnea |
| Forms | Single-dose pen, single-dose vial, KwikPen (4 doses), multi-dose vial (4 doses) |
| Half-life | About 5–6 days |
| Storage | Refrigerator; single-dose forms up to 21 days at ≤30 °C |
| Self-pay price | $299–$699 per 4 doses (checked November 13, 2026) |
| Boxed warning | Thyroid C-cell tumors in rats; not for people with MTC or MEN 2 history |
Each row has its own page: dosage chart, vials, KwikPen, cost and side effects.
What results does Zepbound give?
In the main trial, average weight change after 72 weeks was −15% on 5 mg, −19.5% on 10 mg and −20.9% on 15 mg, versus −3.1% on placebo.[5] In the sleep apnea trials, breathing interruptions fell by 25.3 to 29.3 events per hour at 52 weeks, versus about 5 on placebo.[6] Details: tirzepatide for weight loss and Zepbound for sleep apnea.
Who should not use Zepbound?
The label rules out people with a personal or family history of medullary thyroid carcinoma, people with MEN 2, and anyone with a known serious allergy to tirzepatide or its ingredients.[1] It also says to stop Zepbound when a pregnancy is recognized.[1]
Eli Lilly and Zepbound: key dates
Eli Lilly makes Zepbound and has added new forms and uses since 2023.[2]
| Date | Event |
|---|---|
| Nov 8, 2023[8] | FDA approval for chronic weight management; launch list price $1,059.87 |
| Aug 27, 2024[11] | First single-dose vials (2.5 and 5 mg) on Lilly self-pay |
| Dec 20, 2024[4] | Approval for obstructive sleep apnea with obesity |
| Jan 7, 2026[10] | Multi-dose vial added to the label |
| Feb 23, 2026[9] | KwikPen launched in the U.S. |
| Aug 28, 2026[1] | Current label version |
Related
- Zepbound vs MounjaroSame drug, two labels
- Zepbound vs WegovyHead-to-head results
- Tirzepatide dosage calculatorDoses in units
Frequently asked questions
What is Zepbound?
How does Zepbound work?
It activates GIP and GLP-1 receptors, which reduces appetite and calorie intake and slows stomach emptying.[1]
Who makes Zepbound?
Eli Lilly and Company, which also makes Mounjaro, the same molecule approved for type 2 diabetes.[2]
Is Zepbound the same as Mounjaro?
Both contain tirzepatide at the same strengths, but Zepbound is approved for weight management and sleep apnea and Mounjaro for type 2 diabetes.[1]
Sources
- Zepbound (tirzepatide) injection: prescribing information, Medication Guide and Instructions for Use
- Drugs@FDA: NDA 217806 (Zepbound) approval history and supplement letters
- FDA approves new medication for chronic weight management
- FDA approves first medication for obstructive sleep apnea
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
- Malhotra A et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA)
- Zepbound on LillyDirect: formats and self-pay prices
- FDA approves Lilly's Zepbound (tirzepatide) for chronic weight management
- Zepbound now available in multi-dose KwikPen
- Zepbound supplement approval letter S-037 (multi-dose vial)
- Lilly releases Zepbound single-dose vials, expanding supply and access